Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
Scott S, Marin E, Maples K, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Kaufman J, Lonial S, Nooka A. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood Cancer Journal 2023, 13: 191. PMID: 38114481, PMCID: PMC10730907, DOI: 10.1038/s41408-023-00963-y.Peer-Reviewed Original ResearchProphylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration
Marin E, Scott S, Maples K, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Kaufman J, Lonial S, Nooka A. Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration. Blood 2023, 142: 2008. DOI: 10.1182/blood-2023-189878.Peer-Reviewed Original ResearchCytokine release syndromeGrade 3 cytokine release syndromeSeverity of CRSB-cell maturation antigenProphylactic cohortRelease syndromeMedian durationRRMM patientsAdditional patientsREMS programT-cell engaging therapiesGrade 1Institutional guidelinesDose of steroidsFirst full doseDays of dischargeEmory University HospitalCD38 monoclonal antibodyUsage of steroidsCellular Therapy criteriaDose delaysNeurotoxicity syndromeOutpatient administrationT cell surfaceTocilizumab group